

107506359

1/4

PCT REQUEST

UCL-052-PCT

Original (for SUBMISSION) - printed on 07.03.2002 12:12:34 PM

0	For receiving Office use only	
0-1	International Application No.	
0-2	International Filing Date	
0-3	Name of receiving Office and "PCT International Application"	
0-4	Form - PCT/RO/101 PCT Request	
0-4-1	Prepared using	PCT-EASY Version 2.92 (updated 01.01.2002)
0-5	Petition	
	The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty	
0-6	Receiving Office (specified by the applicant)	European Patent Office (EPO) (RO/EP)
0-7	Applicant's or agent's file reference	UCL-052-PCT
I	Title of invention	METHOD FOR DIAGNOSING AND TREATING PREDISPOSITION FOR ACCELERATED AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
II	Applicant	
II-1	This person is:	applicant only
II-2	Applicant for	all designated States except US
II-4	Name	UNIVERSITE CATHOLIQUE DE LOUVAIN
II-5	Address:	Place de l'Université 1 B-1348 Louvain-la-Neuve Belgium
II-6	State of nationality	BE
II-7	State of residence	BE
II-8	Telephone No.	+32 10 47 24 97
II-9	Facsimile No.	+32 10 47 48 30
III-1	Applicant and/or inventor	
III-1-1	This person is:	applicant and inventor
III-1-2	Applicant for	US only
III-1-4	Name (LAST, First)	DEVUYST, Olivier
III-1-5	Address:	31 Avenue Général Lartigue B-1200 Bruxelles Belgium
III-1-6	State of nationality	BE
III-1-7	State of residence	BE

PCT REQUEST

UCL-052-PCT

Original (for SUBMISSION) - printed on 07.03.2002 12:12:34 PM

III-2.	Applicant and/or inventor	
III-2-1	This person is:	applicant and inventor
III-2-2	Applicant for	US only
III-2-4	Name (LAST, First)	PERSU, Alexandre
III-2-5	Address:	25 Avenue Gilbert Mullie, bte 42 B-1200 Bruxelles Belgium
III-2-6	State of nationality	BE
III-2-7	State of residence	BE
IV-1	Agent or common representative; or address for correspondence The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:	agent
IV-1-1	Name (LAST, First)	BRANTS, Johan, Philippe, Emile
IV-1-2	Address:	De Clercq, Brants & Partners E. Gevaertdreef 10 a B-9830 Sint-Martens-Latem Belgium
IV-1-3	Telephone No.	+32 9 280 23 40
IV-1-4	Facsimile No.	+32 9 280 23 45
IV-1-5	e-mail	info@dcbbpatent.com
IV-2	Additional agent(s)	additional agent(s) with same address as first named agent
IV-2-1	Name(s)	DE CLERCQ, Ann
V	Designation of States	
V-1	Regional Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	AP: GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW and any other State which is a Contracting State of the Harare Protocol and of the PCT EA: AM AZ BY KG KZ MD RU TJ TM and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT EP: AT BE CH&LI CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR and any other State which is a Contracting State of the European Patent Convention and of the PCT OA: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG and any other State which is a member State of OAPI and a Contracting State of the PCT

PCT REQUEST

UCL-052-PCT


Original (for SUBMISSION) - printed on 07.03.2002 12:12:34 PM

V-2	National Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH&LI CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW	
V-5	Precautionary Designation Statement In addition to the designations made under items V-1, V-2 and V-3, the applicant also makes under Rule 4.9(b) all designations which would be permitted under the PCT except any designation(s) of the State(s) indicated under item V-6 below. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit.		
V-6	Exclusion(s) from precautionary designations	NONE	
VI	Priority claim	NONE	
VII-1	International Searching Authority Chosen	European Patent Office (EPO) (ISA/EP)	
VIII	Declarations	Number of declarations	
VIII-1	Declaration as to the identity of the inventor	-	
VIII-2	Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent	-	
VIII-3	Declaration as to the applicant's entitlement, as at the international filing date, to claim the priority of the earlier application	-	
VIII-4	Declaration of inventorship (only for the purposes of the designation of the United States of America)	-	
VIII-5	Declaration as to non-prejudicial disclosures or exceptions to lack of novelty	-	
IX	Check list	number of sheets	electronic file(s) attached
IX-1	Request (including declaration sheets)	4	-
IX-2	Description	33	-
IX-3	Claims	3	-
IX-4	Abstract	1	EZABST00.TXT
IX-5	Drawings	7	-
IX-7	TOTAL	48	
	Accompanying items	paper document(s) attached	electronic file(s) attached
IX-8	Fee calculation sheet	✓	-
IX-17	PCT-EASY diskette	-	Diskette

PCT REQUEST

UCL-052-PCT

Original (for SUBMISSION) - printed on 07.03.2002 12:12:34 PM

IX-19	Figure of the drawings which should accompany the abstract	
IX-20	Language of filing of the international application	English
X-1	Signature of applicant, agent or common representative	
X-1-1	Name (LAST, First)	BRANTS, Johan, Philippe, Emile

FOR RECEIVING OFFICE USE ONLY

10-1	Date of actual receipt of the purported international application	
10-2	Drawings:	
10-2-1	Received	
10-2-2	Not received	
10-3	Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application	
10-4	Date of timely receipt of the required corrections under PCT Article 11(2)	
10-5	International Searching Authority	ISA/EP
10-6	Transmittal of search copy delayed until search fee is paid	

FOR INTERNATIONAL BUREAU USE ONLY

11-1	Date of receipt of the record copy by the International Bureau	
------	--	--

PCT (ANNEX - FEE CALCULATION SHEET)

UCL-052-PCT

Original (for SUBMISSION) - printed on 07.03.2002 12:12:34 PM

(This sheet is not part of and does not count as a sheet of the international application)

0	For receiving Office use only	
0-1	International Application No.	
0-2	Date stamp of the receiving Office	
0-4	Form - PCT/RO/101 (Annex)	
0-4-1	PCT Fee Calculation Sheet Prepared using	PCT-EASY Version 2.92 (updated 01.01.2002)
0-9	Applicant's or agent's file reference	UCL-052-PCT
2	Applicant	UNIVERSITE CATHOLIQUE DE LOUVAIN, et al.
12	Calculation of prescribed fees	fee amount/multiplier Total amounts (EUR)
12-1	Transmittal fee T	⇒ 100
12-2-1	Search fee S	⇒ 945
12-2-2	International search to be carried out by	EP
12-3	International fee	
	Basic fee	
	(first 30 sheets) b1	444
12-4	Remaining sheets	18
12-5	Additional amount (X)	10
12-6	Total additional amount b2	180
12-7	b1 + b2 = B	624
12-8	Designation fees	
	Number of designations contained in international application	93
12-9	Number of designation fees payable (maximum 5)	5
12-10	Amount of designation fee (X)	96
12-11	Total designation fees D	480
12-12	PCT-EASY fee reduction R	-137
12-13	Total International fee (B+D-R) I	⇒ 967
12-17	TOTAL FEES PAYABLE (T+S+I+P)	⇒ 2,012
12-19	Mode of payment	

VALIDATION LOG AND REMARKS

13-2-1	Validation messages Request	Green? The title of the invention shall be short and precise. Please verify.
13-2-4	Validation messages Priority	Green? No priority of an earlier application has been claimed. Please verify

PCT (ANNEX - FEE CALCULATION SHEET)

UCL-052-PCT

Original (for SUBMISSION) - printed on 07.03.2002 12:12:34 PM

13-2-7	Validation messages Contents	Yellow! The power of attorney or a copy of the general power of attorney will need to be furnished unless all applicants sign the request form.
		Green? Figure of the drawings which should accompany the abstract not specified. Please verify.
13-2-9	Validation messages Payment	Yellow The Payment page has not been completed.

Original (for **SUBMISSION**) - printed on 07.03.2002 12:12:34 PM.**PCT-EASY INFORMATION SHEET**

(For applicant use only, DO NOT submit this sheet with the international application)

VALIDATION LOG

Green?	Request The title of the invention shall be short and precise. Please verify.
Green?	Priority No priority of an earlier application has been claimed. Please verify
Yellow!	Contents The power of attorney or a copy of the general power of attorney will need to be furnished unless all applicants sign the request form.
Green?	Figure of the drawings which should accompany the abstract not specified. Please verify.
Yellow	Payment The Payment page has not been completed.

Before submitting the International Application, please carefully verify that:

- the information contained on printed Request form is correct;
- Box X of the Request form has been signed;
- all elements of the international application as indicated in Boxes VIII and IX of the Request form have been attached; and,
- the diskette containing the PCT-EASY zip file of the International Application has been enclosed and has been clearly labeled "PCT-EASY", with the applicant's or agent's file reference, and the first applicant's name.

ATTENTION

DO NOT modify any indications on the Request form printout. The electronic version of the PCT-EASY application has been locked. If an error or an omission is discovered at this time, you must reopen the stored form for submission, perform necessary amendments and immediately resubmit the form. Finally, a NEW submission diskette must be created manually by resending the corrected stored form to the diskette. The previously created printout and submission diskette must be destroyed in order to prevent the possibility of erroneously sending it to the RO.

Present invention provides a method for diagnosing a predisposition to accelerated autosomal dominant polycystic kidney disease (ADPKD) in a human subject. Present invention also provides a diagnostic kit for detecting predisposition for accelerated ADPKD in human subject. In addition, present invention provides a method for treating a human subject predisposed to develop accelerated ADPKD using NO-enhancing compounds.